NCT04061811 (SONGBIRD) is a clinical trial of Diagnostic biomarker study in Heart Failure, sponsored by Hannover Medical School.

Who is sponsoring NCT04061811?

NCT04061811 is sponsored by Hannover Medical School.

What drugs are being tested in NCT04061811?

Interventions in NCT04061811: Diagnostic biomarker study.

What condition does NCT04061811 study?

NCT04061811 studies Heart Failure, End Stage Renal Disease.

Is NCT04061811 still recruiting?

NCT04061811 is currently completed. Last updated 20 August 2019.

Last reviewed 2019-08-20 · How we verify

NCT04061811: SONGBIRD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients

Completed Last updated 20 August 2019

What this trial tests

trial testing Diagnostic biomarker study in Heart Failure in 153 participants. Completed in 28 February 2019.

Timeline

1 August 2018

Primary endpoint
28 February 2019

28 February 2019

Quick facts

Lead sponsor	Hannover Medical School
Status	Completed
Study type	OBSERVATIONAL
Enrollment	153
Start date	1 August 2018
Primary completion	28 February 2019
Estimated completion	28 February 2019
Sites	2 locations across France, Germany

Drugs / interventions tested

Diagnostic biomarker study

Conditions studied

Heart Failure — all drugs for Heart Failure →
End Stage Renal Disease — all drugs for End Stage Renal Disease →

Sponsor

Hannover Medical School

Who can join

18 and older, any sex, with Heart Failure or End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objectives: The aim of this study is to determine whether growth differentiation factor-15 (GDF15) and circulating neprilysin (cNEP) improve the diagnosis of congestive heart failure (HF) in patients on dialysis. Background: Dialysis patients are at increased risk of HF. However, diagnostic utility of NT-proBNP as a biomarker is decreased in patients on dialysis. GDF15 and cNEP are biomarkers of distinct mechanisms that may contribute to HF pathophysiology in such cohorts. Methods: We compare circulating concentrations of NT-proBNP, GDF15, and cNEP along with NEP activity in patients on chronic dialysis without and with HF, as diagnosed by clinical parameters and post-dialysis echocardiography. We use correlation, linear and logistic regression as well as receiver operating characteristic (ROC) analyses.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD).
Claus R, Berliner D, Bavendiek U, Vodovar N, et al · · 2020 · cited 22× · PMID 32002632 · DOI 10.1007/s00392-020-01597-x

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Hannover Medical School trials

Trials by the same sponsor.

NCT07384039 — Exercise Training in Patients With Myeloproliferative Neoplasms · NA · not yet recruiting
NCT06740747 — Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia · NA · recruiting
NCT06795516 — Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation · terminated
NCT06603311 — Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of · NA · active not recruiting
NCT06493006 — Promoting Sustainable and Active Mobility Among Employees and Students · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04061811 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hannover Medical School
Last refreshed: 20 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04061811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing